DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma or Ocular Hypertension
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Trial Timeline
Jul 2, 2016 → Apr 28, 2017
NCT ID
NCT02822742About DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005% is a phase 3 stage product being developed by Santen Pharmaceutical for Primary Open Angle Glaucoma or Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02822742. Target conditions include Primary Open Angle Glaucoma or Ocular Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Primary Open Angle Glaucoma or Ocular Hypertension were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02822742 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma or Ocular Hypertension